$468.00
0.12% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Vertex Pharmaceuticals Stock price

$468.00
-6.29 1.33% 1M
+56.15 13.63% 6M
+61.11 15.02% YTD
+123.68 35.92% 1Y
+269.95 136.30% 3Y
+286.67 158.09% 5Y
+373.51 395.29% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.57 0.12%
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Key metrics

Market capitalization $120.79b
Enterprise Value $115.93b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.23
P/S ratio (TTM) P/S ratio 11.70
P/B ratio (TTM) P/B ratio 8.17
Revenue growth (TTM) Revenue growth 10.32%
Revenue (TTM) Revenue $10.32b
EBIT (operating result TTM) EBIT $-391.00m
Free Cash Flow (TTM) Free Cash Flow $-1.18b
Cash position $5.80b
EPS (TTM) EPS $-2.03
P/E forward negative
P/S forward 11.22
EV/Sales forward 10.77
Short interest 1.72%
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

21x Buy
60%
11x Hold
31%
3x Sell
9%

Analyst Opinions

35 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
60%
Hold
31%
Sell
9%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
10,323 10,323
10% 10%
100%
- Direct Costs 1,401 1,401
22% 22%
14%
8,922 8,922
9% 9%
86%
- Selling and Administrative Expenses 1,139 1,139
32% 32%
11%
- Research and Development Expense 7,965 7,965
138% 138%
77%
-182 -182
105% 105%
-2%
- Depreciation and Amortization 209 209
34% 34%
2%
EBIT (Operating Income) EBIT -391 -391
110% 110%
-4%
Net Profit -490 -490
115% 115%
-5%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Neutral
Seeking Alpha
2 days ago
Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Morgan Stanley Conference Call September 5, 2024 11:30 AM ET Company Participants Reshma Kewalramani - President and CEO Charlie Wagner - CFO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley.
Neutral
Seeking Alpha
3 days ago
Vertex Pharmaceuticals, a leader in Cystic Fibrosis treatment, reported strong financials in Q2 but faces limited growth in CF due to high market penetration. Despite a GAAP net loss in Q2, Vertex remains highly profitable, with promising assets like Casgevy and Suzetrigine poised for future growth. Vertex's high valuation ratios suggest potential overvaluation, but its focused pipeline and blo...
Positive
The Motley Fool
8 days ago
Eli Lilly is a growth machine that never runs out of opportunities. Novo Nordisk is still gaining momentum.
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 5,400
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today